Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy

被引:0
|
作者
De Lucia, Anna [1 ]
Mazzotti, Lucia [1 ,2 ]
Gaimari, Anna [1 ,2 ]
Zurlo, Matteo [1 ]
Maltoni, Roberta [3 ]
Cerchione, Claudio [4 ]
Bravaccini, Sara [5 ]
Delmonte, Angelo [6 ]
Crino, Lucio [6 ]
de Souza, Patricia Borges [1 ]
Pasini, Luigi [1 ,10 ]
Nicolini, Fabio [1 ]
Bianchi, Fabrizio [7 ]
Juan, Manel [8 ]
Calderon, Hugo [8 ]
Magnoni, Chiara [1 ,2 ]
Gazzola, Luca [1 ,2 ]
Ulivi, Paola [9 ]
Mazza, Massimiliano [1 ]
机构
[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Adv Cellular Therapies & Rare Tumors Unit, Meldola, Italy
[2] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy
[3] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Healthcare Adm, Meldola, Italy
[4] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Hematol Unit, Meldola, Italy
[5] Kore Univ Enna, Dept Med & Surg, Enna, Italy
[6] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Med Oncol Dept, Meldola, Italy
[7] Fdn IRCCS Casa Sollievo Sofferenza, Unit Canc Biomarker, San Giovanni Rotondo, FG, Italy
[8] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Dept Immunol, Barcelona, Spain
[9] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Translat Oncol Unit, Meldola, Italy
[10] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Meldola, FC, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
non-small cell lung cancer (NSCLC); tumor microenvironment (TME); tyrosine kinase inhibitors (TKIs); immune checkpoint inhibitors (ICIs); chimeric antigen receptor (CAR) T cell therapy; CHIMERIC ANTIGEN RECEPTOR; CAR-T-CELLS; TERTIARY LYMPHOID STRUCTURES; GROWTH-FACTOR RECEPTOR; OPEN-LABEL; EGFR-MUTATION; 1ST-LINE TREATMENT; ACQUIRED-RESISTANCE; IMMUNE CELLS; SOLID TUMORS;
D O I
10.3389/fimmu.2025.1515748
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past decades, significant progress has been made in the understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting in the development of novel strategies for early detection and wide-ranging care approaches. Since their introduction, over 20 years ago, targeted therapies with tyrosine kinase inhibitors (TKIs) have revolutionized the treatment landscape for NSCLC. Nowadays, targeted therapies remain the gold standard for many patients, but still they suffer from many adverse effects, including unexpected toxicity and intrinsic acquired resistance mutations, which lead to relapse. The adoption of immune checkpoint inhibitors (ICIs) in 2015, has offered exceptional survival benefits for patients without targetable alterations. Despite this notable progress, challenges remain, as not all patients respond favorably to ICIs, and resistance to therapy can develop over time. A crucial factor influencing clinical response to immunotherapy is the tumor microenvironment (TME). The TME is pivotal in orchestrating the interactions between neoplastic cells and the immune system, influencing tumor growth and treatment outcomes. In this review, we discuss how the understanding of this intricate relationship is crucial for the success of immunotherapy and survey the current state of immunotherapy intervention, with a focus on forthcoming and promising chimeric antigen receptor (CAR) T cell therapies in NSCLC. The TME sets major obstacles for CAR-T therapies, creating conditions that suppress the immune response, inducing T cell exhaustion. To enhance treatment efficacy, specific efforts associated with CAR-T cell therapy in NSCLC, should definitely focus TME-related immunosuppression and antigen escape mechanisms, by combining CAR-T cells with immune checkpoint blockades.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] Personalized immunotherapy for advanced non-small cell lung cancer
    Herbst, Roy S.
    ANNALS OF ONCOLOGY, 2015, 26 : 16 - 16
  • [32] Immunotherapy and the Tumor Microenvironment in Brain Metastases from Non-Small Cell Lung Cancer: Challenges and Future Directions
    Wang, Meng
    Yang, Jihua
    Wang, Shuai
    Gill, Harjot
    Cheng, Haiying
    CURRENT ONCOLOGY, 2025, 32 (03)
  • [33] Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists
    Costantini, Adrien
    Katsikas, Theodoros
    Bostantzoglou, Clementine
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2020, 16 (01) : 5 - 10
  • [34] Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer
    Sacco, Paola Claudia
    Maione, Paolo
    Rossi, Antonio
    Bareschino, Maria Anna
    Schettino, Clorinda
    Guida, Cesare
    Elmo, Massimo
    Ambrosio, Rita
    Barbato, Valentina
    Zeppa, Rosario
    Palazzolo, Giovanni
    Gridelli, Cesare
    TARGETED ONCOLOGY, 2011, 6 (03) : 171 - 180
  • [35] The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
    Melosky, Barbara
    Wheatley-Price, Paul
    Juergens, Rosalyn A.
    Sacher, Adrian
    Leighl, Natasha B.
    Tsao, Ming-Sound
    Cheema, Parneet
    Snow, Stephanie
    Liu, Geoffrey
    Card, Paul B.
    Chu, Quincy
    LUNG CANCER, 2021, 160 : 136 - 151
  • [36] Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer
    Paola Claudia Sacco
    Paolo Maione
    Antonio Rossi
    Maria Anna Bareschino
    Clorinda Schettino
    Cesare Guida
    Massimo Elmo
    Rita Ambrosio
    Valentina Barbato
    Rosario Zeppa
    Giovanni Palazzolo
    Cesare Gridelli
    Targeted Oncology, 2011, 6 : 171 - 180
  • [37] Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
    Rodak, Olga
    Peris-Diaz, Manuel David
    Olbromski, Mateusz
    Podhorska-Okolow, Marzenna
    Dziegiel, Piotr
    CANCERS, 2021, 13 (18)
  • [38] Molecularly-targeted therapies for non-small cell lung cancer
    Ramalingam, S
    Belani, CP
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (15) : 2667 - 2679
  • [39] Targeted therapies in combination with chemotherapy in non-small cell lung cancer
    Johnson, David H.
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4451S - 4457S
  • [40] Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
    Patrick R. Halliday
    Collin M. Blakely
    Trever G. Bivona
    Current Oncology Reports, 2019, 21